Onychomycosis, a fungal infection of the nail, affects millions of people worldwide. It’s estimated that about 5% of the global population deals with this condition, and it accounts for a large percentage of all nail problems. Onychomycosis isn’t just a cosmetic issue; it can really affect a person’s quality of life.
Treatments for onychomycosis have traditionally included topical antifungals, oral medications, and even surgical removal of the nail. However, these methods often have drawbacks, leading to less-than-ideal results.
Enter tavaborole, a new topical treatment for toenail onychomycosis. The tavaborole brand name is KERYDIN. It’s part of a class of antifungals called oxaboroles, and it offers a topical alternative that may have fewer systemic side effects than taking pills. That’s a big plus for people who want to avoid the potential risks associated with oral medications.
This article will provide a detailed look at tavaborole (KERYDIN), including how it works, how effective it is, its safety profile, and where it fits into the overall treatment landscape for onychomycosis. We’ll explore the science behind this medication and help you understand if it might be a good option for you or someone you know.